Muscle

Muscle Wasting Disease (MWD) in Cachexia and Sarcopenia

Heat exposure promotes sarcopenia via gut microbiota-derived metabolites.

The unprecedented rise in global ambient temperatures in the last decade has significantly impacted human health, yet how heat exposure affects the development of sarcopenia remains enigmatic. Here, we demonstrate that chronic heat exposure induces skeletal muscle volume loss, leading...

๐Ÿ—“๏ธ 2024-10-29
๐Ÿ“ฐ Publication: Aging Cell
Read MoreHeat exposure promotes sarcopenia via gut microbiota-derived metabolites.

Comment on 'Myosteatosis and Muscle Loss Impact Liver Transplant Outcomes in Male Patients With Hepatocellular Carcinoma' by Lu etย al.

๐Ÿ—“๏ธ 2024-10-20
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreComment on 'Myosteatosis and Muscle Loss Impact Liver Transplant Outcomes in Male Patients With Hepatocellular Carcinoma' by Lu etย al.

Durable Muscle Extracellular Matrix Engineered with Adhesive Phenolic Moieties for Effective Skeletal Muscle Regeneration in Muscle Atrophy.

Muscle atrophy detrimentally impacts health and exacerbates physical disability, leading to increased mortality. In particular, sarcopenia, aging-related degenerative muscle loss, necessitates urgent remedies. Current approaches for treating muscle atrophy include exercise and nutrition, while drug exploration remains in its early...

๐Ÿ—“๏ธ 2024-10-17
๐Ÿ“ฐ Publication: Advanced Healthcare Materials
Read MoreDurable Muscle Extracellular Matrix Engineered with Adhesive Phenolic Moieties for Effective Skeletal Muscle Regeneration in Muscle Atrophy.

Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss?

Recent studies have shown that pharmacologic weight loss with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and combination therapies is approaching magnitudes achieved with surgery. However, as more weight loss is achieved, there is concern for potential adverse effects on muscle...

๐Ÿ—“๏ธ 2024-10-14
๐Ÿ“ฐ Publication: Circulation
Read MoreMuscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss?

Emerging Targets and Treatments for Sarcopenia: A Narrative Review.

Sarcopenia is characterized by the progressive loss of skeletal muscle mass, strength, and function, significantly impacting overall health and quality of life in older adults. This narrative review explores emerging targets and potential treatments for sarcopenia, aiming to provide a...

๐Ÿ—“๏ธ 2024-09-27
Read MoreEmerging Targets and Treatments for Sarcopenia: A Narrative Review.

Masseter Muscle Volume and Its Association with Sarcopenia and Muscle Determinants in Older Japanese Adults: the Bunkyo Health Study.

Sarcopenia has been with a decrease in masseter muscle (MM) thickness in high-risk older populations. However, the relationship between sarcopenia and determinants of MM volume (MMV) in the general elderly population remains unclear. In a cross-sectional study of 1,484 older...

๐Ÿ—“๏ธ 2024-10-14
๐Ÿ“ฐ Publication: Archives Of Medical Research
Read MoreMasseter Muscle Volume and Its Association with Sarcopenia and Muscle Determinants in Older Japanese Adults: the Bunkyo Health Study.

Nutritional strategies for improving sarcopenia outcomes in older adults: A narrative review.

Sarcopenia is characterized by a decline in muscle strength, generalized loss of skeletal muscle mass, and impaired physical performance, which are common outcomes used to screen, diagnose, and determine severity of sarcopenia in older adults. These outcomes are associated with...

๐Ÿ—“๏ธ 2024-10-01
๐Ÿ“ฐ Publication: Pharmacology Research & Perspectives
Read MoreNutritional strategies for improving sarcopenia outcomes in older adults: A narrative review.

Mitochondrial pathways and sarcopenia in the geroscience era.

Sarcopenia is associated with structural, ultrastructural, and molecular abnormalities of skeletal muscle. Mitochondrial dysfunction is a pivotal factor involved in muscle aging and sarcopenia. Mitochondrial bioenergetics are significantly reduced in muscles of older adults which is associated with whole-body aerobic...

๐Ÿ—“๏ธ 2024-10-19
๐Ÿ“ฐ Publication: Journal Of Nutrition Health & Aging
Read MoreMitochondrial pathways and sarcopenia in the geroscience era.

Impact of sarcopenia and muscle strength on postoperative complication risk following pancreatic resection.

The association between sarcopenia and postoperative complications has been widely reported in patients with cancer. Yet, the lack of standardized population-specific diagnostic cut-off points and assessments of muscle strength is hampering prospective clinical utilization. Therefore, we aimed to examine the...

๐Ÿ—“๏ธ 2024-10-11
Read MoreImpact of sarcopenia and muscle strength on postoperative complication risk following pancreatic resection.

Frailty or sarcopenia: which is a better indicator of mortality risk in older adults?

Despite the different conditions, frailty and sarcopenia overlap regarding their common link: the assessment of walking speed and muscle strength. This study aimed to compare the frailty phenotype to the sarcopenia using different cut-off points for low grip strength to...

๐Ÿ—“๏ธ 2024-10-11
๐Ÿ“ฐ Publication: Journal Of Epidemiology And Community Health
Read MoreFrailty or sarcopenia: which is a better indicator of mortality risk in older adults?

Myofiber-specific FoxP1 knockout protects against pancreatic cancer-induced muscle wasting in male but not female mice.

Cancer cachexia affects up to 80% of cancer patients and results in reduced quality of life and survival. We previously demonstrated that the transcriptional repressor Forkhead box P1 (FoxP1) is upregulated in skeletal muscle of cachectic mice and people with...

๐Ÿ—“๏ธ 2024-09-21
Read MoreMyofiber-specific FoxP1 knockout protects against pancreatic cancer-induced muscle wasting in male but not female mice.

Sarcopenic obesity in patients with head and neck cancer is predictive of critical weight loss during radiotherapy.

The impact of computed tomography-defined sarcopenia on outcomes in head and neck cancer has been well described. Sarcopenic obesity (SO) (depleted muscle mass combined with obesity) may pose a more serious risk than either condition alone. We investigated SO and...

๐Ÿ—“๏ธ 2024-09-30
๐Ÿ“ฐ Publication: British Journal Of Nutrition
Read MoreSarcopenic obesity in patients with head and neck cancer is predictive of critical weight loss during radiotherapy.

LRRK2 Gene Mutation Causes Skeletal Muscle Impairment in Animal Model of Parkinson's Disease.

While the gradually aggravated motor and non-motor disorders of Parkinson's disease (PD) lead to progressive disability and frequent falling, skeletal muscle impairment may contribute to this condition. The leucine-rich repeat kinase2 (LRRK2) is a common disease-causing gene in PD. Little...

๐Ÿ—“๏ธ 2024-09-23
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreLRRK2 Gene Mutation Causes Skeletal Muscle Impairment in Animal Model of Parkinson's Disease.

The crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia.

With limited treatment options, cachexia remains a major challenge for patients with cancer. Characterizing the interplay between tumor cells and the immune microenvironment may help identify potential therapeutic targets for cancer cachexia. Herein, we investigate the critical role of macrophages...

๐Ÿ—“๏ธ 2024-03-29
๐Ÿ“ฐ Publication: Cancer Cell
Read MoreThe crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia.

Effect of sirolimus on muscle in inclusion body myositis observed with magnetic resonance imaging and spectroscopy.

Finding sensitive clinical outcome measures has become crucial in natural history studies and therapeutic trials of neuromuscular disorders. Here, we focus on 1-year longitudinal data from quantitative magnetic resonance imaging (MRI) and phosphorus magnetic resonance spectroscopy (P MRS) in a...

๐Ÿ—“๏ธ 2024-04-13
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreEffect of sirolimus on muscle in inclusion body myositis observed with magnetic resonance imaging and spectroscopy.

The BET inhibitor JQ1 targets fat metabolism and counteracts obesity.

Obesity, one of the most frequent health problems in the adult population, is a condition characterized by excessive white adipose tissue accumulation and accompanied by the increased risk to develop other disorders such as type II diabetes, cardiovascular disorders, physical...

๐Ÿ—“๏ธ 2024-02-15
๐Ÿ“ฐ Publication: Journal Of Advanced Research
Read MoreThe BET inhibitor JQ1 targets fat metabolism and counteracts obesity.

Muscle Wasting Disease (MWD) in Cachexia and Sarcopenia

Weight loss is the hallmark of any progressive acute or chronic disease state. In its extreme form, it involves a significant lean body mass (including skeletal muscle), and fat loss. Skeletal muscle provides a fundamental basis for human function, enabling locomotion and respiration. Muscle wasting is related to a poor quality of life and increased morbidity/ mortality.

Two common but distinct conditions characterized by a loss of skeletal muscle mass are sarcopenia and cachexia. Sarcopenia, cachexia, and anorexic disorders (protein-energy malnutrition) represent the major causes of muscle-wasting disorders.

It has been known for millennia that muscle and fat wasting leads to poor outcomes including deaths in chronic disease states.

It is usually accompanied by physical inactivity, decreased mobility, slow gait, and poor physical endurance which are also common features of the frailty syndrome.

Fig. 1 โ€“ Framework for the suggested classification of MWD by disease etiology and disease progression.

Both cachexia and sarcopenia are characterized by an important muscle dysfunction that leads to increased morbidity and mortality.

Fig. 2 โ€“ The cachexia/ sarcopenia pyramid. Both lead to muscle dysfunction.

References

Kalantar-Zadeh K, Rhee C, Sim JJ, Stenvinkel P, Anker SD, Kovesdy CP.ย Why cachexia kills: examining the causality of poor outcomes in wasting conditions.ย J Cachexia Sarcopenia Muscle 2013; 4: 89โ€“94.

Evans WJ, Morley JE, Argilรฉs J, Bales C, Baracos V, Guttridge D, et al.ย Cachexia: a new definition.ย Clin Nutr 2008; 27: 793โ€“799.

Anker SD, Coats AJS, Morley JE, Rosano G, Bernabei R, Haehling S, et al.ย Muscle wasting disease: a proposal for a new disease classification.ย J Cachexia Sarcopenia Muscle 2014; 5: 1โ€“3.

Argiles JM, Busquets S, Stemmler B, Lรณpez-Soriano FJ.ย Cachexia and sarcopenia: mechanisms and potential targets for intervention.ย Current Opinion in Pharmacology 2015; 22: 100โ€“106.

Bowen TS, Schuler G, Adams V.ย Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training.ย J Cachexia Sarcopenia Muscle 2015; 6: 197โ€“207.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!